Navigation Links
Oasmia: FDA Grants Paclical(R) Orphan Drug Designation for Ovarian Cancer in the USA
Date:4/14/2009

UPPSALA, Sweden, April 14 /PRNewswire-FirstCall/ -- Oasmia Pharmaceutical, Uppsala, Sweden, has been granted Orphan Drug designation by the USA FDA of Paclical(R) for the treatment of ovarian cancer. Orphan Drug designation can entail additional assistance from FDA to expedite and optimize drug development and upon approval a seven year market exclusivity is granted.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070918/273312 )

Orphan drug designation is intended to support the clinical development of new drugs in diseases affecting less than 200,000 people. This provides Oasmia with seven year market exclusivity on the indication when the pharmaceutical is approved. There is no direct generic competition during the period and FDA often provides technical and financial assistance to expedite and optimize drug development.

The designation is based on the hypothesis that Paclitaxel is safer than Taxol(R). Oasmia Pharmaceutical is conducting a Phase III study comparing the use of Paclical to Taxol(R) in patients with ovarian cancer. A safety objective is to show the superiority of hypersensitivity reactions.

This designation shows that the FDA has a great confidence in the company and our product. The United States is one of the most important markets for Paclical(R). This decision improves the possibilities for the product, says Julian Aleksov, CEO of Oasmia in a comment.

About Ovarian cancer

Ovarian cancer is a disease with few and unspecific symptoms at its early stages, and is difficult to detect. The numbers of patients that are diagnosed are increasing on a yearly basis. Ovarian cancer is most often diagnosed in women over 50 years of age, but younger women are also affected. The annual incidence of new diagnosed cases is approximately 125 000 women in EU alone. In the USA ovarian cancer accounts for 3 % of all cancer cases and is the fifth leading cause of cancer related deaths in the US.

About Paclical(R)

With the retinoid based unique platform XR-17, Oasmia has managed to produce a water soluble formulation of Paclitaxel (Paclical(R)), that does not require premedication and without the severe Cremophor(R) EL related side effects. The main indication is ovarian cancer. Other planned indications are malignant melanoma and lung cancer (NSCLC).

About Oasmia

Oasmia Pharmaceutical AB develops second and third generation cancer drugs based on nanotechnology for human and veterinary use. The broad portfolio is focused on oncology and contains several promising products in clinical and pre-clinical phase. Oasmia cooperates with leading universities and other biotech companies to discover and optimize substances with a favourable safety profile and better efficacy. The company was founded in 1998 and is based in Uppsala, Sweden.

    For more information, please contact:

    Maria Lunden
    Head of Public Relations
    Oasmia Pharmaceutical AB.
    E-mail: press@oasmia.com
    Phone: +46-0-18-50-54-40
    Information is also available at:
   http://www.ngm.se andhttp://www.oasmia.com


'/>"/>
SOURCE Oasmia Pharmaceutical AB
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. US FDA Grants Orphan Drug Status to Immtechs Pafuramidine for Treatment of African Sleeping Sickness
2. Chinese SFDA Grants Immtech Fast Track Status
3. Ethics Group Asks USAID Inspector General to Investigate Legality of Grants to Soros Groups
4. NTMir Announces Research Grants for Epidemiology and Household Water as Source of Infection
5. FDA Grants Approval to Extend U.S. Enrollment and Clinical Trial
6. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel
7. FDA Grants Priority Review for ACIPHEX(R) (rabeprazole sodium) sNDA for Short-Term Treatment of GERD in Adolescents
8. FDA Grants Priority Review for PROMACTA(R) (eltrombopag)
9. FDA Grants NeoVistas Request to Expand CABERNET Trial to 30 Sites in the U.S.
10. FDA Grants Market Clearance for the LipiScan(TM) Coronary Imaging System Developed by InfraReDx, Inc. - A Novel Spectroscopy System for the Identification of Lipid Core Containing Plaques of Interest in the Coronary Arteries
11. FDA Grants Pediatric Exclusivity for TOPAMAX(R), Extending the Marketing Exclusivity by Six Months
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... 2017 Sherpa Clinical Packaging ( www.sherpaclinical.com ... is pleased to announce the appointment of Kevin Rosenthal as ... Sherpa team to lead Sherpa,s Operations group and ... excellence. Kevin is not new to ... He has extensive experience working for leading pharma ...
(Date:1/24/2017)... YORK , January 24, 2017 ... the fastest growing industries in the United States ... medicinal use in 2016. In addition, Proposition 64, the California ... for and 42.87% against on November 8, 2016. This outcome ... allowed to use and to grow a certain amount of ...
(Date:1/24/2017)... 24, 2017   Keneric Healthcare , a ... effective patient care products, today announced their partnership ... the reach of both companies by leveraging their ... Angelini Pharma Inc . ... include Keneric Healthcare,s RTD™ Wound Dressing (antibacterial/antifungal).  RTD™ ...
Breaking Medicine Technology:
(Date:1/24/2017)... Houston, TEXAS (PRWEB) , ... January 24, 2017 ... ... firm and solution provider of enterprise software products, today announced a strategic partnership ... enable Element Blue users to access and analyze their Fusion platform for building ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... was recently accepted as a Registered Trademark by the United States Patent and ... a similar name which could confuse consumers into thinking that other products are ...
(Date:1/24/2017)... ... January 24, 2017 , ... Twelve startups have been ... 2017 Cupid's Cup Entrepreneurship Competition. Chaired by Under Armour Founder and CEO Kevin ... will showcase their businesses on February 6, 2017, at Under Armour’s global headquarters ...
(Date:1/24/2017)... ... January 24, 2017 , ... ... it has officially formed a distribution partnership with Byers Scientific & Manufacturing ... management industry. , Through the agreement, OMI Industries formulated a special version of ...
(Date:1/24/2017)... , ... January 24, 2017 , ... Center for ... century leadership, has named Hector M. Chavez, Manager, Employee & Labor Relations at ... - as its Hispanic Leader of the Month. City of Hope is committed to ...
Breaking Medicine News(10 mins):